The role of NAFLD in cardiometabolic disease: An update

• Type of Material: Article
• Authors: Sarah Faasse, Emory University; Hayley Braun, Emory University; Miriam Benedicta Vos, Emory University
• Language: English
• Date: 2018-09-02
• Publisher: F1000Research
• Publication Version: Final Published Version
• Copyright Statement: © 2018 Faasse S et al.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.12688/f1000research.12028.1
• Title of Journal or Parent Work: F1000Research
• ISSN: 2046-1402
• Volume: 7
• Start Page: 170
• End Page: 170
• Grant/Funding Information: This work was supported through a grant provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R21 HD0809056-01.
• Keywords: non-alcoholic fatty liver disease; type 2 diabetes mellitus; cardiometabolic disease
• Research Categories: Health Sciences, General; Health Sciences, Pathology

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world, yet the complex pathogenesis remains to be fully elucidated. The prevalence of NAFLD has risen precipitously in recent years and is now a leading indication for liver transplantation. New waitlist registrants with non-alcoholic steatohepatitis-induced cirrhosis increased by 170% from 2004 to 2013. In addition, patients with NAFLD are at increased risk of both cardiovascular disease and type II diabetes. In this update, recent studies contributing to the understanding of the place of NAFLD in cardiometabolic disease will be discussed.